ITRMF (Iterum Therapeutics) Total Receivables: $0.55 Mil (As of Sep. 2025)


What is Iterum Therapeutics Total Receivables?

Iterum Therapeutics ITRMF +18.86% Total Receivables is $0.55 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Iterum Therapeutics's Total Receivables for the quarter that ended in Sep. 2025 was $0.55 Mil.

Iterum Therapeutics Total Receivables Related Terms

Iterum Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Total Receivables Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only 0.87 1.21 0.42 0.23 0.07

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.07 0.02 0.08 0.55

Iterum Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.55 Mil mean?
Iterum Therapeutics (ITRMF) has a Total Receivables of $0.55 Mil as of Sep. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' Total Receivables too high?
Iterum Therapeutics' current Total Receivables is $0.55 Mil.
How does Iterum Therapeutics' Total Receivables compare to ENSC and PPCB?
Iterum Therapeutics' Total Receivables of $0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current Total Receivables is $0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Total Receivables of $0.55 Mil. The current Total Receivables is $0.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Total Receivables is $0.55 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.